|
1
|
Bolton-Maggs PH and Pasi KJ: Haemophilias
A and B. Lancet. 361:1801–1809. 2003.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Iorio A, Stonebraker JS, Chambost H,
Makris M, Coffin D, Herr C and Germini F: Data and Demographics
Committee of the World Federation of Hemophilia. Establishing the
prevalence and prevalence at birth of hemophilia in males: A
meta-analytic approach using national registries. Ann Intern Med.
171:540–546. 2019.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Kavaklı K, Antmen B, Okan V, Şahin F,
Aytaç S, Balkan C, Berber E, Kaya Z, Küpesiz A and Zülfikar B: Gene
therapy in haemophilia: Literature review and regional perspectives
for Turkey. Ther Adv Hematol. 13(20406207221104591)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bolous NS, Bhatt N, Bhakta N, Neufeld EJ,
Davidoff AM and Reiss UM: Gene therapy and hemophilia: Where do we
go from here? J Blood Med. 13:559–580. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
World Federation of Hemophilia: The report
on the WFH annual global survey 2020: World Federation of
Hemophilia, 2021. Available from: https://www1.wfh.org/publications/files/pdf-2045.pdf.
|
|
6
|
Kadhim KAR, Al-Lami FH and Baldawi KH:
Epidemiological profile of hemophilia in Baghdad-Iraq. Inquiry.
56(46958019845280)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Abdulsalam AH, Al-Rahal NK and Ghiath Y:
Inherited bleeding disorders in pediatric patients; experience of
the national referral center in Iraq. Indian J Hematol Blood
Transfus. 37:96–100. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hassan S, Monahan RC, Mauser-Bunschoten
EP, van Vulpen LFD, Eikenboom J, Beckers EAM, Hooimeijer L, Ypma
PF, Nieuwenhuizen L, Coppens M, et al: Mortality, life expectancy,
and causes of death of persons with hemophilia in the Netherlands
2001-2018. J Thromb Haemost. 19:645–653. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Coffin D, Gouider E, Konkle B, Hermans C,
Lambert C, Diop S, Ayoub E, Tootoonchian E, Youttananukorn T, Dakik
P, et al: The world federation of hemophilia world bleeding
disorders registry: Insights from the first 10,000 patients. Res
Pract Thromb Haemost. 7(102264)2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Taresh AK and Hassan MK: Inhibitors among
patients with hemophilia in Basra, Iraq-A single center experience.
Niger J Clin Pract. 22:416–421. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lateef IA: Evaluation of the clinical
status of patients with inherited bleeding disorders in
Diyala-Iraq. Diyala J Medicine. 9:23–29. 2015.
|
|
12
|
Lateef IA, Hamood HJ and Khaleel OA:
Spectrum of hemophilia in Diyala-Iraq. Diyala J Medicine. 10:53–58.
2016.
|
|
13
|
Sharma A, Mathew ME, Sriganesh V and Reiss
UM: Gene therapy for haemophilia. Cochrane Database Syst Rev.
4(CD010822)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Srivastava A, Santagostino E, Dougall A,
Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV,
Windyga J, et al: WFH guidelines for the management of hemophilia.
Haemophilia. 26:1–158. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Nathwani AC: Gene therapy for hemophilia.
Hematology Am Soc Hematol Educ Program. 2019:1–8. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang X, Shin SC, Chiang AF, Khan I, Pan D,
Rawlings DJ and Miao CH: Intraosseous delivery of lentiviral
vectors targeting factor VIII expression in platelets corrects
murine hemophilia A. Mol Ther. 23:617–626. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Doncel SS, Mosquera GA, Pelaez RG, Cortes
JM, Rico CA, Cadavid FJ, Plazas NR, Amar IAP, Siado JEP, Rey FAP,
et al: Genetic characterization of the factor VIII gene in a cohort
of colombian patients with severe hemophilia A with inhibitors.
Hematol Rep. 14:149–154. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hassan MM and Jabber AD: Identification of
factor VIII gene mutations in Iraqi patient with hemophilia A. Int
J Med Res Prof. 2:192–199. 2016.
|
|
19
|
Abdulqader AMR, Mohammed AI, Rachid S,
Ghoraishizadeh P and Mahmood SN: Identification of the intron 22
and intron 1 inversions of the factor VIII gene in Iraqi Kurdish
patients with hemophilia A. Clin Appl Thromb Hemost.
26(1076029619888293)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lisowski L, Staber JM, Wright JF and
Valentino LA: The intersection of vector biology, gene therapy, and
hemophilia. Res Pract Thromb Haemost. 5(e12586)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Palmer TD, Thompson AR and Miller AD:
Production of human factor IX in animals by genetically modified
skin fibroblasts: Potential therapy for hemophilia B. Blood.
73:438–445. 1989.PubMed/NCBI
|
|
22
|
Nathwani AC, Tuddenham EG, Rangarajan S,
Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ,
Harrington C, et al: Adenovirus-associated virus vector-mediated
gene transfer in hemophilia B. N Engl J Med. 365:2357–2365.
2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Niemeyer GP, Herzog RW, Mount J, Arruda
VR, Tillson DM, Hathcock J, van Ginkel FW, High KA and Lothrop CD
Jr: Long-term correction of inhibitor-prone hemophilia B dogs
treated with liver-directed AAV2-mediated factor IX gene therapy.
Blood. 113:797–806. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liao G, Nayak S, Regueiro JR, Berger SB,
Detre C, Romero X, de Waal Malefyt R, Chatila TA, Herzog RW and
Terhorst C: GITR engagement preferentially enhances proliferation
of functionally competent CD4+ CD25+ FoxP3+ regulatory T cells. Int
Immunol. 22:259–270. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cooper M, Nayak S, Hoffman BE, Terhorst C,
Cao O and Herzog RW: Improved induction of immune tolerance to
factor IX by hepatic AAV-8 gene transfer. Hum Gene Ther.
20:767–776. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mátrai J, Chuah MKL and VandenDriessche T:
Preclinical and clinical progress in hemophilia gene therapy. Curr
Opin Hematol. 17:387–392. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Rangarajan S, Walsh L, Lester W, Perry D,
Madan B, Laffan M, Yu H, Vettermann C, Pierce GF, Wong WY and Pasi
KJ: AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J
Med. 377:2519–2530. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Guo XL, Chung TH, Qin Y, Zheng J, Zheng H,
Sheng L, Wynn T and Chang LJ: Hemophilia gene therapy: New
development from bench to bed side. Curr Gene Ther. 19:264–273.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xu L, Nichols TC, Sarkar R, McCorquodale
S, Bellinger DA and Ponder KP: Absence of a desmopressin response
after therapeutic expression of factor VIII in hemophilia A dogs
with liver-directed neonatal gene therapy. Proc Natl Acad Sci USA.
102:6080–6085. 2005.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Milani M, Canepari C, Liu T, Biffi M,
Russo F, Plati T, Curto R, Patarroyo-White S, Drager D, Visigalli
I, et al: Liver-directed lentiviral gene therapy corrects
hemophilia A mice and achieves normal-range factor VIII activity in
non-human primates. Nat Commun. 13(2454)2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tsui LV, Kelly M, Zayek N, Rojas V, Ho K,
Ge Y, Moskalenko M, Mondesire J, Davis J, Roey MV, et al:
Production of human clotting Factor IX without toxicity in mice
after vascular delivery of a lentiviral vector. Nat Biotechnol.
20:53–57. 2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Stein CS, Kang Y, Sauter SL, Townsend K,
Staber P, Derksen TA, Martins I, Qian J, Davidson BL and McCray PB
Jr: In vivo treatment of hemophilia A and mucopolysaccharidosis
type VII using nonprimate lentiviral vectors. Mol Ther. 3:850–856.
2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Dull T, Zufferey R, Kelly M, Mandel RJ,
Nguyen M, Trono D and Naldini L: A third-generation lentivirus
vector with a conditional packaging system. J Virol. 72:8463–8471.
1998.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kuether EL, Schroeder JA, Fahs SA, Cooley
BC, Chen Y, Montgomery RR, Wilcox DA and Shi Q: Lentivirus-mediated
platelet gene therapy of murine hemophilia A with pre-existing
anti-factor VIII immunity. J Thromb Haemost. 10:1570–1580.
2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Roth DA, Tawa NE Jr, O'Brien JM, Treco DA
and Selden RF: Factor VIII Transkaryotic Therapy Study Group.
Nonviral transfer of the gene encoding coagulation factor VIII in
patients with severe hemophilia A. N Engl J Med. 344:1735–1742.
2001.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Spira J, Plyushch OP, Andreeva TA and
Andreev Y: Prolonged bleeding-free period following prophylactic
infusion of recombinant factor VIII reconstituted with pegylated
liposomes. Blood. 108:3668–3673. 2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Di Minno G, Cerbone AM, Coppola A, Cimino
E, Di Capua M, Pamparana F, Tufano A and Di Minno MN: Longer-acting
factor VIII to overcome limitations in haemophilia management: The
PEGylated liposomes formulation issue. Haemophilia. 16:2–6.
2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lu DR, Zhou JM, Zheng B, Qiu XF, Xue JL,
Wang JM, Meng PL, Han FL, Ming BH and Wang XP: Stage I clinical
trial of gene therapy for hemophilia B. Sci China B. 36:1342–1351.
1993.PubMed/NCBI
|
|
39
|
Manno CS, Pierce GF, Arruda VR, Glader B,
Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, et al:
Successful transduction of liver in hemophilia by AAV-factor IX and
limitations imposed by the host immune response. Nat Med.
12:342–347. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
40
|
Crudele JM, Finn JD, Siner JI, Martin NB,
Niemeyer GP, Zhou S, Mingozzi F, Lothrop CD Jr and Arruda VR: AAV
liver expression of FIX-Padua prevents and eradicates FIX inhibitor
without increasing thrombogenicity in hemophilia B dogs and mice.
Blood. 125:1553–1561. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Von Drygalski A, Giermasz A, Castaman G,
Key NS, Lattimore S, Leebeek FWG, Miesbach W, Recht M, Long A, Gut
R, et al: Etranacogene dezaparvovec (AMT-061 phase 2b): Normal/near
normal FIX activity and bleed cessation in hemophilia B. Blood Adv.
3:3241–3247. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Pipe SW, Leebeek FWG, Recht M, Key NS,
Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P,
Coppens M, et al: Gene therapy with etranacogene dezaparvovec for
hemophilia B. N Engl J Med. 388:706–718. 2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Pipe SW, Reddy KR and Chowdary P: Gene
therapy: Practical aspects of implementation. Haemophilia. 28
(Suppl 4):S44–S52. 2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Pasi KJ, Laffan M, Rangarajan S, Robinson
TM, Mitchell N, Lester W, Symington E, Madan B, Yang X, Kim B, et
al: Persistence of haemostatic response following gene therapy with
valoctocogene roxaparvovec in severe haemophilia A. Haemophilia.
27:947–956. 2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Pasi KJ, Rangarajan S, Mitchell N, Lester
W, Symington E, Madan B, Laffan M, Russell CB, Li M, Pierce GF and
Wong WY: Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for
hemophilia A. N Engl J Med. 382:29–40. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A,
Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K,
et al: Valoctocogene roxaparvovec gene therapy for hemophilia A. N
Engl J Med. 386:1013–1025. 2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Long BR, Veron P, Kuranda K, Hardet R,
Mitchell N, Hayes GM, Wong WY, Lau K, Li M, Hock MB, et al: Early
phase clinical immunogenicity of valoctocogene roxaparvovec, an
AAV5-mediated gene therapy for hemophilia A. Mol Ther. 29:597–610.
2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Visweshwar N, Harrington TJ, Leavitt AD,
Konkle BA, Giermasz A, Stine K, et al: Updated results of the alta
study, a phase 1/2 study of giroctocogene fitelparvovec
(PF-07055480/SB-525) gene therapy in adults with severe hemophilia
A. Blood. 138 (Suppl 1)(564)2021.
|
|
49
|
Elkouby L, Armour SM, Toso R, DiPietro M,
Davidson RJ, Nguyen GN, Willet M, Kutza S, Silverberg J, Frick J,
et al: Preclinical assessment of an optimized AAV-FVIII vector in
mice and non-human primates for the treatment of hemophilia A. Mol
Ther Methods Clin Dev. 24:20–29. 2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
George LA, Monahan PE, Eyster ME, Sullivan
SK, Ragni MV, Croteau SE, Rasko JEJ, Recht M, Samelson-Jones BJ,
MacDougall A, et al: Multiyear factor VIII expression after AAV
gene transfer for hemophilia A. N Engl J Med. 385:1961–1973.
2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Barbon E, Ayme G, Mohamadi A, Ottavi JF,
Kawecki C, Casari C, Verhenne S, Marmier S, van Wittenberghe L,
Charles S, et al: Single-domain antibodies targeting antithrombin
reduce bleeding in hemophilic mice with or without inhibitors. EMBO
Mol Med. 12(e11298)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Setten RL, Rossi JJ and Han SP: The
current state and future directions of RNAi-based therapeutics. Nat
Rev Drug Discov. 18:421–446. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Patnaik MM and Moll S: Inherited
antithrombin deficiency: A review. Haemophilia. 14:1229–1239.
2008.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Pasi KJ, Rangarajan S, Georgiev P, Mant T,
Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR, Hegemann I, et
al: Targeting of antithrombin in hemophilia A or B with RNAi
therapy. N Engl J Med. 377:819–828. 2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Dargaud Y, Béguin S, Lienhart A, Al Dieri
R, Trzeciak C, Bordet JC, Hemker HC and Negrier C: Evaluation of
thrombin generating capacity in plasma from patients with
haemophilia A and B. Thromb Haemost. 93:475–480. 2005.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Segurado OG, Jiang R and Pipe SW:
Challenges and opportunities when transitioning from in vivo gene
replacement to in vivo CRISPR/Cas9 therapies-a spotlight on
hemophilia. Expert Opin Biol Ther. 22:1091–1098. 2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Chen H, Shi M, Gilam A, Zheng Q, Zhang Y,
Afrikanova I, Li J, Gluzman Z, Jiang R, Kong LJ, et al: Hemophilia
A ameliorated in mice by CRISPR-based in vivo genome editing of
human factor VIII. Sci Rep. 9(16838)2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Anguela XM, Sharma R, Doyon Y, Miller JC,
Li H, Haurigot V, Rohde ME, Wong SY, Davidson RJ, Zhou S, et al:
Robust ZFN-mediated genome editing in adult hemophilic mice. Blood.
122:3283–3287. 2013.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Shi Q: Platelet-targeted gene therapy for
hemophilia. Mol Ther Methods Clin Dev. 9:100–108. 2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Nayak S and Herzog RW: Progress and
prospects: Immune responses to viral vectors. Gene Ther.
17:295–304. 2010.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Salas D, Kwikkers KL, Zabaleta N, Bazo A,
Petry H, van Deventer SJ, Aseguinolaza GG and Ferreira V:
Immunoadsorption enables successful rAAV5-mediated repeated hepatic
gene delivery in nonhuman primates. Blood Adv. 3:2632–2641.
2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Ferla R, Claudiani P, Savarese M, Kozarsky
K, Parini R, Scarpa M, Donati MA, Sorge G, Hopwood JJ, Parenti G,
et al: Prevalence of anti-adeno-associated virus serotype 8
neutralizing antibodies and arylsulfatase B cross-reactive
immunologic material in mucopolysaccharidosis VI patient candidates
for a gene therapy trial. Hum Gene Ther. 26:145–152.
2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Elmore ZC, Oh DK, Simon KE, Fanous MM and
Asokan A: Rescuing AAV gene transfer from neutralizing antibodies
with an IgG-degrading enzyme. JCI Insight.
5(e139881)2020.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Follenzi A, Santambrogio L and Annoni A:
Immune responses to lentiviral vectors. Curr Gene Ther. 7:306–315.
2007.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Limberis MP, Bell CL, Heath J and Wilson
JM: Activation of transgene-specific T cells following
lentivirus-mediated gene delivery to mouse lung. Mol Ther.
18:143–150. 2010.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Geisler A and Fechner H:
MicroRNA-regulated viral vectors for gene therapy. World J Exp Med.
6:37–54. 2016.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Chen Y, Schroeder JA, Gao C, Li J, Hu J
and Shi Q: In vivo enrichment of genetically manipulated platelets
for murine hemophilia B gene therapy. J Cell Physiol. 236:354–365.
2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Lundstrom K: Viral vectors in gene
therapy: Where do we stand in 2023? Viruses. 15(698)2023.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Nathwani AC, Rosales C, McIntosh J,
Rastegarlari G, Nathwani D, Raj D, Nawathe S, Waddington SN,
Bronson R, Jackson S, et al: Long-term safety and efficacy
following systemic administration of a self-complementary AAV
vector encoding human FIX pseudotyped with serotype 5 and 8 capsid
proteins. Mol Ther. 19:876–885. 2011.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Nathwani AC, Reiss UM, Tuddenham EG,
Rosales C, Chowdary P, McIntosh J, Peruta MD, Lheriteau E, Patel N,
Raj D, et al: Long-term safety and efficacy of factor IX gene
therapy in hemophilia B. N Engl J Med. 371:1994–2004.
2014.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Batty P and Lillicrap D: Hemophilia gene
therapy: Approaching the first licensed product. Hemasphere.
5(e540)2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Chandler RJ, LaFave MC, Varshney GK,
Trivedi NS, Carrillo-Carrasco N, Senac JS, Wu W, Hoffmann V,
Elkahloun AG, Burgess SM and Venditti CP: Vector design influences
hepatic genotoxicity after adeno-associated virus gene therapy. J
Clin Invest. 125:870–880. 2015.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Fong S, Rangarajan S and Mitchell N: First
in human liver biopsy study following gene therapy for hemophilia
A. Res Pract Thromb Haemost. 4(3)2020.
|
|
74
|
Marcucci KT, Jadlowsky JK, Hwang WT,
Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF,
Plesa G, Chew A, et al: Retroviral and lentiviral safety analysis
of gene-modified T cell products and infused HIV and oncology
patients. Mol Ther. 26:269–279. 2018.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Arruda VR, Fields PA, Milner R, Wainwright
L, De Miguel MP, Donovan PJ, Herzog RW, Nichols TC, Biegel JA,
Razavi M, et al: Lack of germline transmission of vector sequences
following systemic administration of recombinant AAV-2 vector in
males. Mol Ther. 4:586–592. 2001.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Favaro P, Downey HD, Zhou JS, Wright JF,
Hauck B, Mingozzi F, High KA and Arruda VR: Host and
vector-dependent effects on the risk of germline transmission of
AAV vectors. Mol Ther. 17:1022–1030. 2009.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Food and Drug Administration: Guidance for
industry: Gene therapy clinical trials-Observing subjects for
delayed adverse events. 2006.
|
|
78
|
Leebeek FWG, Meijer K, Coppens M, Kampmann
P, Klamroth R, Schutgens R, Castaman G, Seifried E, Schwaeble J,
Bönig H, et al: AMT-060 gene therapy in adults with severe or
moderate-severe hemophilia B confirm stable FIX expression and
durable reductions in bleeding and factor IX consumption for up to
5 years. Blood. 136(26)2020.
|
|
79
|
Sabatino DE, Lange AM, Altynova ES, Sarkar
R, Zhou S, Merricks EP, Franck HG, Nichols TC, Arruda VR and
Kazazian HH Jr: Efficacy and safety of long-term prophylaxis in
severe hemophilia A dogs following liver gene therapy using AAV
vectors. Mol Ther. 19:442–449. 2011.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Gollomp KL, Doshi BS and Arruda VR: Gene
therapy for hemophilia: Progress to date and challenges moving
forward. Transfus Apher Sci. 58:602–612. 2019.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Samori Z and Badran I: Somatic gene
therapy: Ethical consideration and Islamic Fiqhi perspective. J
Engineering and Applied Sciences. 13:4353–4561. 2018.
|
|
82
|
Bolous NS, Chen Y, Wang H, Davidoff AM,
Devidas M, Jacobs TW, Meagher MM, Nathwani AC, Neufeld EJ, Piras
BA, et al: The cost-effectiveness of gene therapy for severe
hemophilia B: A microsimulation study from the United States
perspective. Blood. 138:1677–1690. 2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Reiss UM, Zhang L and Ohmori T: Hemophilia
gene therapy-New country initiatives. Haemophilia. 27:132–141.
2021.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Goodman C, Berntorp E and Wong O:
International Haemophilia Access Strategy Council. Alternative
payment models for durable and potentially curative therapies: The
case of gene therapy for haemophilia A. Haemophilia. 28:27–34.
2022.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Sharma A, Mathew ME, Sriganesh V and Reiss
UM: Gene therapy for haemophilia. Cochrane Database Syst Rev.
12(CD010822)2016.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Drummond MF, Neumann PJ, Sullivan SD,
Fricke FU, Tunis S, Dabbous O and Toumi M: Analytic considerations
in applying a general economic evaluation reference case to gene
therapy. Value Health. 22:661–668. 2019.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Peyvandi F, Garagiola I and Young G: The
past and future of haemophilia: Diagnosis, treatments, and its
complications. Lancet. 388:187–197. 2016.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Pierce GF and Coffin D: Members of the WFH
Gene Therapy Round Table Program Committee and Organizing
Committee. The 1st WFH gene therapy round table: Understanding the
landscape and challenges of gene therapy for haemophilia around the
world. Haemophilia. 25:189–194. 2019.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Doshi BS and Arruda VR: Gene therapy for
hemophilia: What does the future hold? Ther Adv Hematol. 9:273–293.
2018.PubMed/NCBI View Article : Google Scholar
|
|
90
|
George LA, Sullivan SK, Giermasz A, Rasko
JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S,
Teitel J, et al: Hemophilia B gene therapy with a
high-specific-activity factor IX variant. N Engl J Med.
377:2215–2227. 2017.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Miesbach W, Meijer K, Coppens M, Kampmann
P, Klamroth R, Schutgens R, Tangelder M, Castaman G, Schwäble J,
Bonig H, et al: Gene therapy with adeno-associated virus vector
5-human factor IX in adults with hemophilia B. Blood.
131:1022–1031. 2018.PubMed/NCBI View Article : Google Scholar
|
|
92
|
George LA, Ragni MV, Rasko JEJ, Raffini
LJ, Samelson-Jones BJ, Ozelo M, Hazbon M, Runowski AR, Wellman JA,
Wachtel K, et al: Long-Term follow-up of the first in human
intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for
severe hemophilia B. Mol Ther. 28:2073–2082. 2020.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Konkle BA, Walsh CE, Escobar MA, Josephson
NC, Young G, Von Drygalski A, McPhee SWJ, Samulski RJ, Bilic I, de
la Rosa M, et al: BAX 335 hemophilia B gene therapy clinical trial
results: Potential impact of CpG sequences on gene expression.
Blood. 137:763–774. 2021.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Chowdary P, Shapiro S, Makris M, Evans G,
Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, et al:
Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia
B. N Engl J Med. 387:237–247. 2022.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Xue F, Li H, Wu X, Liu W, Zhang F, Tang D,
Chen Y, Wang W, Chi Y, Zheng J, et al: Safety and activity of an
engineered, liver-tropic adeno-associated virus vector expressing a
hyperactive Padua factor IX administered with prophylactic
glucocorticoids in patients with haemophilia B: A single-centre,
single-arm, phase 1, pilot trial. Lancet Haematol. 9:e504–e513.
2022.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Powell JS, Ragni MV, White GC II, Lusher
JM, Hillman-Wiseman C, Moon TE, Cole V, Ramanathan-Girish S, Roehl
H, Sajjadi N, et al: Phase 1 trial of FVIII gene transfer for
severe hemophilia A using a retroviral construct administered by
peripheral intravenous infusion. Blood. 102:2038–2045.
2003.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Mahlangu J, Kaczmarek R, Von Drygalski A,
Shapiro S, Chou SC, Ozelo MC, Kenet G, Peyvandi F, Wang M, Madan B,
et al: Two-Year outcomes of valoctocogene roxaparvovec therapy for
hemophilia A. N Engl J Med. 388:694–705. 2023.PubMed/NCBI View Article : Google Scholar
|
